Christian Ottensmeier
Overview
Explore the profile of Christian Ottensmeier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
2221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicholas B, Bailey A, McCann K, Johnson P, Elliott T, Ottensmeier C, et al.
J Proteome Res
. 2025 Jan;
24(2):729-741.
PMID: 39772544
Non-small cell lung cancer (NSCLC) is frequently diagnosed late and has poor survival. The two predominant subtypes of NSCLC, adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), are currently differentially diagnosed...
2.
Mathews I, Saminathan P, Henglin M, Liu M, Nadig N, Fang C, et al.
medRxiv
. 2024 Aug;
PMID: 39148854
Immune related adverse events (irAEs) after immune checkpoint blockade (ICB) therapy occur in a significant proportion of cancer patients. To date, the circulating mediators of ICB-irAEs remain poorly understood. Using...
3.
Kors T, Meier M, Muhlenbruch L, Betzler A, Oliveri F, Bens M, et al.
Front Immunol
. 2024 Aug;
15:1408173.
PMID: 39136024
Introduction: The human leukocyte antigen complex (HLA) is essential for inducing specific immune responses to cancer by presenting tumor-associated peptides (TAP) to T cells. Overexpressed tumor associated antigens, mainly cancer-testis...
4.
Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, et al.
Cell Rep Med
. 2024 Feb;
5(3):101435.
PMID: 38417447
Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This...
5.
Meyer M, Dinh H, Alimadadi A, Araujo D, Chatterjee N, Gutierrez N, et al.
Front Immunol
. 2023 Nov;
14:1224045.
PMID: 38022639
Purpose: Due to their abundance in the blood, low RNA content, and short lifespan, neutrophils have been classically considered to be one homogenous pool. However, recent work has found that...
6.
Anpalakhan S, Huddar P, Behrouzi R, Signori A, Cave J, Comins C, et al.
Front Oncol
. 2023 Jun;
13:1163768.
PMID: 37324003
Background: The Spinnaker study evaluated survival outcomes and prognostic factors in patients with advanced non-small-cell lung cancer receiving first-line chemoimmunotherapy in the real world. This sub-analysis assessed the immunotherapy-related adverse...
7.
Ghorani E, Quartagno M, Blackhall F, Gilbert D, OBrien M, Ottensmeier C, et al.
Lancet Oncol
. 2023 May;
24(5):e219-e227.
PMID: 37142383
Increasing evidence suggests that some immunotherapy dosing regimens for patients with advanced cancer could result in overtreatment. Given the high costs of these agents, and important implications for quality of...
8.
Jones R, Mielgo A, Schmid M, Bury D, Andrews T, Burdak-Rothkamm S, et al.
Br J Surg
. 2023 Apr;
110(9):1108-1111.
PMID: 37075549
No abstract available.
9.
Anpalakhan S, Huddar P, Behrouzi R, Signori A, Cave J, Comins C, et al.
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36675262
GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10−20%. GCSF has...
10.
Vimalachandran D, Jones R, Dickson E, Seehra J, Acheson A, Griffiths E, et al.
Br J Surg
. 2022 Sep;
110(3):306-309.
PMID: 36168210
No abstract available.